Browsing by Subject "Taxoids"

Article

Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study

Briassoulis, E. Ch; Pentheroudakis, George; Timotheadou, H.; Rammou, D.; Pavlidis, Nicholas; Fountzilas, George (2004)

We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...

Article

Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?

Pentheroudakis, George; Briassoulis, E. Ch; Karavasilis, V.; Fountzilas, George; Xeros, N.; Samelis, G.; Samantas, E.; Pavlidis, Nicholas (2005)

Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases ...

Article

Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support

Briassoulis, E. Ch; Froudarakis, M. E.; Milionis, Haralampos J.; Peponis, I. A.; Constantopoulos, S. H.; Pavlidis, Nicholas (2000)

Several cancer therapeutic agents have been associated with pulmonary toxicity. Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema ...

Article

Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study

Pentheroudakis, George; Briassoulis, E. Ch; Kalofonos, H. P.; Fountzilas, George; Economopoulos, T.; Samelis, G.; Koutras, A. K.; Karina, M.; Xiros, N.; Samantas, E.; Bamias, A. T.; Pavlidis, Nicholas (2008)

Introduction. Taxane/platinum combinations exhibit synergistic cytotoxicity and activity against a broad range of solid tumours. We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer ...

Article

Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II study

Fountzilas, George; Nikolaides, C.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Samelis, G.; Aravantinos, Gerasimos; Pavlidis, Nicholas (2000)

A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline- resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a ...

Article

Docetaxel-induced enterocolitis: A serious and potentially fatal adverse event

Boussios, Stergios; Pentheroudakis, George; Kamina, S.; Katsanos, K.; Pavlidis, Nicholas (2011)

Article

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group

Nikolaides, C.; Dimopoulos, M. A.; Samantas, E.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Fountzilas, George; Razi, E. D.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)

Background: Gemcitabine and vinorelbine have shown activity in breast cancer. A phase II trial was initiated in order to evaluate the response rate (RR) and time to progression (TTP) of the combination of the two drugs in ...

Article

Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study

Skarlos, Dimosthenis V.; Kalofonos, H. P.; Fountzilas, George; Dimopoulos, M. A.; Pavlidis, Nicholas; Razi, E. D.; Economopoulos, T.; Pectasides, Dimitrios; Gogas, H.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Klouvas, G. D.; Kyratzis, G.; Aravantinos, Gerasimos (2005)

Background: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory ...

Article

Interaction pharmacokinetis of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel

Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Soulti, K.; Piperidou, C.; Pavlidis, Nicholas (2004)

Purpose: To investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans. Methods: ...

Article

Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women

Pentheroudakis, George; Fountzilas, George; Bafaloukos, Dimitrios; Koutsoukou, V.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Samantas, E.; Kalofonos, H. P.; Gogas, H.; Pavlidis, Nicholas (2006)

Introduction. Breast cancer patients developing liver metastases have traditionally been considered to make up a poor prognosis group with median survival rates of less than 6 months. We retrospectively analysed clinicopathologic ...

Article

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer

Mauri, D.; Polyzos, N. P.; Salanti, G.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2008)

Background: Many systemic nonhormonal regimens have been evaluated across several hundreds of randomized trials in advanced breast cancer. We aimed to quantify the relative merits of these regimens in prolonging survival. ...

Article

Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets

Pavlidis, Nicholas (2012)

Cancer of unknown primary sites (CUP) is a compilation of various malignant entities-the majority of which behave aggressively and carry poor prognosis. CUP is classified into two different clinicopathological groups: the ...

Article

Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer

Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Fountzilas, George; Christodoulou, C.; Papadimitriou, C.; Pavlidis, Nicholas; Kalofonos, H. P.; Gogas, H.; Kosmidis, Paraskevas A.; Dimopoulos, M. A. (2003)

Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. ...

Article

Prevention of chemotherapy-induced alopecia using an effective scalp cooling system

Katsimbri, P. P.; Bamias, A. T.; Pavlidis, Nicholas (2000)

Alopecia is a distressing side-effect of cancer treatment. Taxanes (TX), anthracyclines (ANR) and etoposide (ET) have been consistently associated with significant alopecia. We studied an effective scalp cooling system, ...

Article

Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions [1]

Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas (2000)

Article

Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments

Kyrgiou, M.; Salanti, G.; Pavlidis, Nicholas; Paraskevaidis, E.; Ioannidis, J. P. A. (2006)

Background: Numerous randomized trials have compared different chemotherapy regimens in women with ovarian cancer. Although ovarian cancer survival has improved in recent years, the magnitude of these incremental benefits ...

Article

Weekly docetaxel in minimally pretreated cancer patients: A dose- escalation study focused on feasibility and cumulative toxicity of long-term administration

Briassoulis, E. Ch; Karavasilis, V.; Anastasopoulos, D.; Tzamakou, E.; Fountzilas, George; Rammou, D.; Kostadima, Vasiliki; Pavlidis, Nicholas (1999)

Background: Docetaxel is an agent with impressive clinical activity but a rather poor profile of toxicity when given every three weeks. Therefore, optimisation of its clinical use is highly warranted. This is a dose- ...